210-TA), Recombinant Human IL-18/ IL-1F4 stimulates IFN-gamma secretion in the KG-1 human acute myelogenous leukemia cell line in a dose-dependent manner (left-hand graph), as measured by the Human IFN-gamma Quantikine ELISA Kit (Catalog #
DIF50C). Under these conditions, IFN-gamma secretion elicited by Recombinant Human IL-18/ IL-1F4 (40 ng/mL) is neutralized (right-hand graph) by increasing concentrations of Mouse Anti-Human IL-18 R beta /IL-1 R7 Monoclonal Antibody (Catalog # MAB1181). The ND
50 is typically 0.3-1.0 µg/mL." class="big_lightbox">

210-TA), Recombinant Human IL-18/ IL-1F4 stimulates IFN-gamma secretion in the KG-1 human acute myelogenous leukemia cell line in a dose-dependent manner (left-hand graph), as measured by the Human IFN-gamma Quantikine ELISA Kit (Catalog #
DIF50C). Under these conditions, IFN-gamma secretion elicited by Recombinant Human IL-18/ IL-1F4 (40 ng/mL) is neutralized (right-hand graph) by increasing concentrations of Mouse Anti-Human IL-18 R beta /IL-1 R7 Monoclonal Antibody (Catalog # MAB1181). The ND
50 is typically 0.3-1.0 µg/mL." alt="In the presence of Recombinant Human TNF-alpha (20 ng/mL, Catalog #
210-TA), Recombinant Human IL-18/ IL-1F4 stimulates IFN-gamma secretion in the KG-1 human acute myelogenous leukemia cell line in a dose-dependent manner (left-hand graph), as measured by the Human IFN-gamma Quantikine ELISA Kit (Catalog #
DIF50C). Under these conditions, IFN-gamma secretion elicited by Recombinant Human IL-18/ IL-1F4 (40 ng/mL) is neutralized (right-hand graph) by increasing concentrations of Mouse Anti-Human IL-18 R beta /IL-1 R7 Monoclonal Antibody (Catalog # MAB1181). The ND
50 is typically 0.3-1.0 µg/mL." class="big_thumb" />